


Product Information	
Catalog No.	BS10249
Product name	Anti-Human PD-L1/B7-H1 Reference Antibody (Sugemalimab, RUO)
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species reactivity	Human
Host species	Human
Clonality	Monoclonal
Isotype	IgG4-lambda
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Concentration	1mg/ml
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Target	B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274
Expression system	Mammalian Cells
Accession	Q9NZQ7
Endotoxin level	Please contact the lab for this information.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Note	For research use only. Not suitable for clinical or therapeutic use.

Background

Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). In 2015, it was in clinical trials as an immunotherapy for several types of solid tumors. It was under investigation by Genetech/Roche. In April 2016, Roche announced that atezolizumab had been granted fast track status for lung cancer by the FDA. In May 2018, Tecentriq was in combination with Avastin and standard chemotherapy for some patients with lung cancer was granted priority review.

Image Data



SDS-PAGE for Research Grade Sugemalimab

SDS-PAGE